Phenotyping studies to assess the effects of phytopharmaceuticals on in vivo activity of main human cytochrome P450 enzymes

Planta Medica

Volumn 78, Issue 13, 2012, Pages 1428-1457

  Zadoyan, Gregor ^a   Fuhr, Uwe ^a,b  

^a ITECRA GmbH and Co KG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

botanicals; cocktail interaction studies; cytochrome P450; herb drug interaction; herbal products; phytopharmaceuticals

Indexed keywords

ACTEA RACEMOSA EXTRACT; ALPRAZOLAM; ATORVASTATIN; CAFFEINE; CAMELLIA SINENSIS EXTRACT; CHLORZOXAZONE; CYCLOSPORIN; CYTOCHROME P450; DEBRISOQUINE; DESOGESTREL; ECHINACEA PURPUREA EXTRACT; ETHINYLESTRADIOL; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCINE MAX EXTRACT; HYDRASTIS CANADENSIS EXTRACT; HYDROCORTISONE; HYPERICUM PERFORATUM EXTRACT; KAVA EXTRACT; MIDAZOLAM; PLANT EXTRACT; SABAL EXTRACT; SAQUINAVIR; SILYBUM MARIANUM EXTRACT; THEOPHYLLINE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIUM MACROCARPON EXTRACT; VALERIAN;

DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; NONHUMAN; PHENOTYPE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANGIOSPERMS; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; HERB-DRUG INTERACTIONS; HUMANS; PHENOTYPE; PHYTOTHERAPY; PLANT EXTRACTS; SUBSTRATE SPECIFICITY;

ALLIUM SATIVUM; ARALIACEAE; ARECACEAE; ASTERACEAE; CAMELLIA SINENSIS; CLUSIACEAE; ECHINACEA PURPUREA; ERICACEAE; FABACEAE; GINKGO BILOBA; GINKGOACEAE; GLYCINE MAX; HYDRASTIS CANADENSIS; HYPERICUM PERFORATUM; LILIACEAE; PANAX GINSENG; PIPER METHYSTICUM; PIPERACEAE; RANUNCULACEAE; SERENOA REPENS; SILYBUM MARIANUM; THEACEAE; VACCINIUM MACROCARPON; VALERIANA OFFICINALIS; VALERIANACEAE;

EID: 84866136525     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0031-1298536     Document Type: Review

References (147)

1. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. St. Johns wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA: 2000; 97 7500 7502
2. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet: 1991; 337 268 269
3. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktailo" approach. Clin Pharmacol Ther: 2007; 81 270 283
4. Huang SM, Zhang L. Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. Available at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM072101.htm Accessed December 02, 2011
5. European Medicines Agency Guideline on the investigation of drug interactions. Available at http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2010/05/WC500090112.pdf Accessed December 02, 2011
6. US Food and Drug Administration Drug development and drug interactions: table of substrates, inhibitors and inducers. Available at http://www.fda.gov/ Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ ucm093664.htm Accessed December 02, 2011
7. Tanaka E, Kurata N, Yasuhara H. How useful is the "cocktail approacho" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo ? J Clin Pharm Ther: 2003; 28 157 165
8. Zhou H, Tong Z, McLeod JF. "Cocktailo" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol: 2004; 44 120 134
9. Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol: 2009; 68 928 935
10. Zhang L. A regulatory perspective on the utilization of cocktail approach in assessing drug interactions. Available at http://www.fda.gov/downloads/ Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ UCM237160.htm Accessed December 02, 2011
11. Zhang L, Reynolds KS, Zhao P, Huang SM. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol: 2010; 243 134 145
12. US Food and Drug Administration Guidances (Drugs). Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ default.htm Accessed December 02, 2011
13. Ma JD, Nguyen ET, Tsunoda SM, Greenberg HE, Gorski JC, Penzak SR, Lee LS. Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation. Int J Clin Pharmacol Ther: 2010; 48 847 853
14. Fuhr U, Beckmann-Knopp S, Jetter A, Luck H, Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med: 2007; 73 1429 1435
15. Zadoyan G, Rokitta D, Klement S, Dienel A, Hoerr R, Gramatte T, Fuhr U. Effect of Ginkgo biloba special extract EGb 761(R) on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol: 2012; 68 553 560
16. Blumenthal M, Ferrier GKL, Cavaliere C. Total sales of herbal supplements in United States show steady growth. Herbal Gram: 2006; 71 64 66
17. Borrelli F, Capasso R, Izzo AA. Garlic (Allium sativum L.): adverse effects and drug interactions in humans. Mol Nutr Food Res: 2007; 51 1386 1397
18. Lanzotti V. The analysis of onion and garlic. J Chromatogr A: 2006; 1112 3 22
19. Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther: 2009; 8 208 227
20. Butterweck V, Derendorf H. Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clin Pharmacokinet: 2008; 47 383 397
21. Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol: 2003; 55 199 202
22. Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther: 1998; 63 453 464
23. Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res: 2006; 12 4636 4640
24. Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr: 2006; 136 793S 795S
25. Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther: 2003; 74 170 177
26. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis: 2002; 34 234 238
27. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St Johns wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging: 2005; 22 525 539
28. Taylor JA, Weber W, Standish L, Quinn H, Goesling J, McGann M, Calabrese C. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA: 2003; 290 2824 2830
29. Freeman C, Spelman K. A critical evaluation of drug interactions with Echinacea spp. Mol Nutr Food Res: 2008; 52 789 798
30. Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett: 2004; 577 563 569
31. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther: 2004; 75 89 100
32. Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, Stevenson JM, Kovacs JA. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy: 2010; 30 797 805
33. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med: 2003; 3 221 230
34. Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, Matthias A, Lehmann RP, McLachlan AJ. Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol: 2010; 69 508 515
35. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther: 2004; 76 428 440
36. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. Johns wort, and Echinacea. Mol Nutr Food Res: 2008; 52 755 763
37. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol: 2000; 163 1408 1412
38. Markowitz JS, Donovan JL, Devane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther: 2003; 74 536 542
39. Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, Schoenberger NE. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil: 2000; 81 668 678
40. Abdel-Kader R, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A, Muller WE. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res: 2007; 56 493 502
41. Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimers disease. FASEB J: 2007; 21 2400 2408
42. Tchantchou F, Lacor PN, Cao Z, Lao L, Hou Y, Cui C, Klein WL, Luo Y. Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. Int J Alzheimers Dis: 2009; 18 787 798
43. Elovic EP, Zafonte RD. Ginkgo biloba: applications in traumatic brain injury. J Head Trauma Rehabil: 2001; 16 603 607
44. Cohen-Salmon C, Venault P, Martin B, Raffalli-Sebille MJ, Barkats M, Clostre F, Pardon MC, Christen Y, Chapouthier G. Effects of Ginkgo biloba extract (EGb 761) on learning and possible actions on aging. J Physiol: 1997; 91 291 300
45. Thiagarajan G, Chandani S, Harinarayana Rao S, Samuni AM, Chandrasekaran K, Balasubramanian D. Molecular and cellular assessment of Ginkgo biloba extract as a possible ophthalmic drug. Exp Eye Res: 2002; 75 421 430
46. Rioufol G, Pietri S, Culcasi M, Loufoua J, Staat P, Pop C, Drieu K, Ovize M. Ginkgo biloba extract EGb 761 attenuates myocardial stunning in the pig heart. Basic Res Cardiol: 2003; 98 59 68
47. DeFeudis FV. A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry: 2003; 36 S2 S7
48. Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Harmatz JS, Avula B, Khan IA, Goldman P. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol: 2006; 46 214 221
49. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol: 2005; 59 425 432
50. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics: 2004; 14 841 850
51. Lei HP, Wang G, Wang LS, Ou-yang DS, Chen H, Li Q, Zhang W, Tan ZR, Fan L, He YJ, Zhou HH. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother: 2009; 43 726 731
52. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin: 2008; 24 591 599
53. Lei HP, Ji W, Lin J, Chen H, Tan ZR, Hu DL, Liu LJ, Zhou HH. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol: 2009; 68 201 206
54. Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol: 2003; 23 576 581
55. Penzak SR, Busse KH, Robertson SM, Formentini E, Alfaro RM, Davey RT Jr. Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharmacol: 2008; 48 671 680
56. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol: 2006; 46 1290 1298
57. Zuo XC, Zhang BK, Jia SJ, Liu SK, Zhou LY, Li J, Zhang J, Dai LL, Chen BM, Yang GP, Yuan H. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol: 2010; 66 503 509
58. Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy: 2006; 26 1314 1319
59. Zuo Y, Wang C, Zhan J. Separation, characterization, and quantitation of benzoic and phenolic antioxidants in American cranberry fruit by GC-MS. J Agric Food Chem: 2002; 50 3789 3794
60. McKay DL, Blumberg JB. Cranberries (Vaccinium macrocarpon) and cardiovascular disease risk factors. Nutr Rev: 2007; 65 490 502
61. Pham DQ, Pham AQ. Interaction potential between cranberry juice and warfarin. Am J Health Syst Pharm: 2007; 64 490 494
62. Griffiths P. The role of cranberry juice in the treatment of urinary tract infections. Br J Community Nurs: 2003; 8 557 561
63. Ngo N, Yan Z, Graf TN, Carrizosa DR, Kashuba AD, Dees EC, Oberlies NH, Paine MF. Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab Dispos: 2009; 37 514 522
64. Howell AB, Foxman B. Cranberry juice and adhesion of antibiotic-resistant uropathogens. JAMA: 2002; 287 3082 3083
65. Ushijima K, Tsuruoka S, Tsuda H, Hasegawa G, Obi Y, Kaneda T, Takahashi M, Maekawa T, Sasaki T, Koshimizu TA, Fujimura A. Cranberry juice suppressed the diclofenac metabolism by human liver microsomes, but not in healthy human subjects. Br J Clin Pharmacol: 2009; 68 194 200
66. Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther: 2006; 79 125 133
67. Mohammed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, McLachlan AJ. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol: 2008; 154 1691 1700
68. Lilja JJ, Backman JT, Neuvonen PJ. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam - probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther: 2007; 81 833 839
69. Grenier J, Fradette C, Morelli G, Merritt GJ, Vranderick M, Ducharme MP. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther: 2006; 79 255 262
70. Wu Z, Rodgers RP, Marshall AG. Characterization of vegetable oils: detailed compositional fingerprints derived from electrospray ionization fourier transform ion cyclotron resonance mass spectrometry. J Agric Food Chem: 2004; 52 5322 5328
71. Messina M, Messina V. The role of soy in vegetarian diets. Nutrients: 2010; 2 855 888
72. Kishida T, Nagamoto M, Ohtsu Y, Watakabe M, Ohshima D, Nashiki K, Mizushige T, Izumi T, Obata A, Ebihara K. Lack of an inducible effect of dietary soy isoflavones on the mRNA abundance of hepatic cytochrome P-450 isozymes in rats. Biosci Biotechnol Biochem: 2004; 68 508 515
73. Peng WX, Li HD, Zhou HH. Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. Eur J Clin Pharmacol: 2003; 59 237 241
74. Chen Y, Xiao CQ, He YJ, Chen BL, Wang G, Zhou G, Zhang W, Tan ZR, Cao S, Wang LP, Zhou HH. Genistein alters caffeine exposure in healthy female volunteers. Eur J Clin Pharmacol: 2011; 67 347 353
75. Wang G, Xiao CQ, Li Z, Guo D, Chen Y, Fan L, Qian RH, Peng XJ, Hu DL, Zhou HH. Effect of soy extract administration on losartan pharmacokinetics in healthy female volunteers. Ann Pharmacother: 2009; 43 1045 1049
76. Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol: 2003; 43 643 648
77. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs: 2009; 69 1777 1798
78. Lee MH, Jeong JH, Seo JW, Shin CG, Kim YS, In JG, Yang DC, Yi JS, Choi YE. Enhanced triterpene and phytosterol biosynthesis in Panax ginseng overexpressing squalene synthase gene. Plant Cell Physiol: 2004; 45 976 984
79. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci: 2001; 16 S28 S37
80. Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Alternat Complement Med: 2008; 14 715 721
81. Briskin DP. Medicinal plants and phytomedicines. Linking plant biochemistry and physiology to human health. Plant Physiol: 2000; 124 507 514
82. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol: 1999; 55 567 575
83. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St Johns wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol: 2004; 57 592 599
84. Rhyu MR, Lu J, Webster DE, Fabricant DS, Farnsworth NR, Wang ZJ. Black cohosh (Actaea racemosa, Cimicifuga racemosa) behaves as a mixed competitive ligand and partial agonist at the human mu opiate receptor. J Agric Food Chem: 2006; 54 9852 9857
85. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther: 2005; 77 415 426
86. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol: 2006; 46 201 213
87. Borrelli F, Izzo AA. Herb-drug interactions with St Johns wort (Hypericum perforatum): an update on clinical observations. AAPS J: 2009; 11 710 727
88. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. Johns wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci: 2000; 66 PL133 PL139
89. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St Johns wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther: 2001; 70 317 326
90. Wenk M, Todesco L, Krahenbuhl S. Effect of St Johns wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol: 2004; 57 495 499
91. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St Johns Wort: effect on CYP3A4 activity. Clin Pharmacol Ther: 2000; 67 451 457
92. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Effect of St Johns wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA: 2003; 290 1500 1504
93. Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D, Zhou HH. The influence of St Johns Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol: 2004; 44 577 581
94. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH. St Johns wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther: 2004; 75 191 197
95. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St Johns wort-cyclosporine drug interaction. Clin Pharmacol Ther: 2004; 76 330 340
96. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St Johns wort extract. Planta Med: 2005; 71 331 337
97. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B. The extent of induction of CYP3A by St. Johns wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol: 2006; 62 29 36
98. Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H, Lehnfeld R, Frank B, Thurow K, Kundt G, Drewelow B. No clinically relevant CYP3A induction after St. Johns wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol: 2009; 65 81 87
99. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St Johns wort and an oral contraceptive. Clin Pharmacol Ther: 2003; 74 525 535
100. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. Johns Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception: 2005; 71 402 408
101. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St Johns wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol: 2003; 56 683 690
102. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. Induction of imatinib metabolism by Hypericum perforatum. Blood: 2004; 104 1229 1230
103. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St Johns wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther: 2004; 76 323 329
104. Andren L, Andreasson A, Eggertsen R. Interaction between a commercially available St. Johns wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol: 2007; 63 913 916
105. Portoles A, Terleira A, Calvo A, Martinez I, Resplandy G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol: 2006; 46 1188 1194
106. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. St Johns wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther: 2004; 75 298 309
107. Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A. Drug interaction between St Johns Wort and quazepam. Br J Clin Pharmacol: 2004; 58 403 410
108. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. Opposite effects of short-term and long-term St Johns wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther: 2005; 78 25 33
109. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St Johns wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol: 2008; 153 1579 1586
110. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St Johns wort. Lancet: 2000; 355 547 548
111. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther: 2007; 6 110 119
112. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res: 2007; 143 58 65
113. Brantley SJ, Oberlies NH, Kroll DJ, Paine MF. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther: 2010; 332 1081 1087
114. van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res: 2005; 11 7800 7806
115. Lu H, Meng X, Li C, Sang S, Patten C, Sheng S, Hong J, Bai N, Winnik B, Ho CT, Yang CS. Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab Dispos: 2003; 31 452 461
116. Feng WY. Metabolism of green tea catechins: an overview. Curr Drug Metab: 2006; 7 755 809
117. Zhang Q, Fu H, Pan J, He J, Ryota S, Hara Y, Wang Y, Lubet RA, You M. Effect of dietary Polyphenon E and EGCG on lung tumorigenesis in A/J Mice. Pharm Res: 2010; 27 1066 1071
118. Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC, Schantz SP. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev: 1998; 7 351 354
119. Yang TT, Koo MW. Chinese green tea lowers cholesterol level through an increase in fecal lipid excretion. Life Sci: 2000; 66 411 423
120. Yang TT, Koo MW. Inhibitory effect of Chinese green tea on endothelial cell-induced LDL oxidation. Atherosclerosis: 2000; 148 67 73
121. Zhong Z, Froh M, Connor HD, Li X, Conzelmann LO, Mason RP, Lemasters JJ, Thurman RG. Prevention of hepatic ischemia-reperfusion injury by green tea extract. Am J Physiol Gastrointest Liver Physiol: 2002; 283 G957 G964
122. Oyama J, Maeda T, Kouzuma K, Ochiai R, Tokimitsu I, Higuchi Y, Sugano M, Makino N. Green tea catechins improve human forearm endothelial dysfunction and have antiatherosclerotic effects in smokers. Circ J: 2010; 74 578 588
123. Oyama J, Maeda T, Sasaki M, Kozuma K, Ochiai R, Tokimitsu I, Taguchi S, Higuchi Y, Makino N. Green tea catechins improve human forearm vascular function and have potent anti-inflammatory and anti-apoptotic effects in smokers. Intern Med: 2010; 49 2553 2559
124. Persson IA, Persson K, Hagg S, Andersson RG. Effects of green tea, black tea and Rooibos tea on angiotensin-converting enzyme and nitric oxide in healthy volunteers. Public Health Nutr: 2010; 13 730 737
125. Nantz MP, Rowe CA, Bukowski JF, Percival SS. Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition: 2009; 25 147 154
126. Donovan JL, Chavin KD, Devane CL, Taylor RM, Wang JS, Ruan Y, Markowitz JS. Green tea (Camellia sinensis) extract does not alter cytochrome p 450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos: 2004; 32 906 908
127. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, Alberts DS. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev: 2006; 15 2473 2476
128. Kennedy DO, Wightman EL. Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Adv Nutr: 2011; 2 32 50
129. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol: 1999; 51 505 512
130. Houghton PJ. The biological activity of Valerian and related plants. J Ethnopharmacol: 1988; 22 121 142
131. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav: 1982; 17 65 71
132. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med: 1985; 144 148
133. Dorn M. [Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative study]. Forsch Komplementarmed Klass Naturheilkd: 2000; 7 79 84
134. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry: 2000; 33 47 53
135. Donovan JL, DeVane CL, Chavin KD, Wang JS, Gibson BB, Gefroh HA, Markowitz JS. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos: 2004; 32 1333 1336
136. Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J Ethnopharmacol: 2004; 93 153 160
137. Thompson R, Ruch W, Hasenohrl RU. Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava). Hum Psychopharmacol: 2004; 19 243 250
138. Kennedy DA, Seely D. Clinically based evidence of drug-herb interactions: a systematic review. Expert Opin Drug Saf: 2010; 9 79 124
139. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther: 2008; 83 61 69
140. Brown PN, Roman MC. Determination of hydrastine and berberine in goldenseal raw materials, extracts, and dietary supplements by high-performance liquid chromatography with UV: collaborative study. J AOAC Int: 2008; 91 694 701
141. Lancaster HM, Davidson AL. Commercial pharmaceutical preparations: 4. Hydrastis - golden seal. Can Med Assoc J: 1927; 17 1317 1320
142. Chatterjee P, Franklin MR. Human cytochrome p 450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos: 2003; 31 1391 1397
143. Yi S, Cho JY, Lim KS, Kim KP, Kim J, Kim BH, Hong JH, Jang IJ, Shin SG, Yu KS. Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on cytochrome P450 activities in healthy volunteers. Basic Clin Pharmacol Toxicol: 2009; in press
144. Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, Li Q, Zhang W, Wang G, Lei HP, Hu DL, Wang D, Zhou HH. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol: 2009; 65 403 409
145. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol: 2006; 545 51 64
146. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila): 2010; 3 1168 1175
147. Chen Y, Liu WH, Chen BL, Fan L, Han Y, Wang G, Hu DL, Tan ZR, Zhou G, Cao S, Zhou HH. Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. Ann Pharmacother: 2010; 44 1038 1045